Clinical Trial Update: A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating CMX001 (brincidofovir) for safety and dose determination in infants with neonatal herpes simplex virus infection involving the cent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Virus Infection
• Neonatal Herpes Simplex Virus Infection

Drugs mentioned

• CMX001 (brincidofovir)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Herpes Simplex Virus | Phase 1, Phase 2 | Status: WITHDRAWN